Clearpoint Neuro is trading 11.1% higher at $15.52 after Stifel reiterated its Buy rating and $22 price target, citing the company’s cell- and gene-therapy focus.
- The analyst action is the clearest identified catalyst for the September 22, 2026 move.
- Broader sentiment was supportive, with the Nasdaq Composite up 0.61%.
- No new company filing or major announcement was identified.